Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour intraocular pressure and ocular perfusion pressure study of tafluprost
ChiCTR-OPC-17013229Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tafluprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: Intraocular pressure. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
tafluprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on ChiCTR-OPC-17013229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013229.